Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:80531 |
Name | dedifferentiated liposarcoma |
Definition | A liposarcoma that is characterized as a high-grade tumor that occurs when a lower-grade tumor changes and creates new high-grade cells. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer musculoskeletal system cancer connective tissue cancer liposarcoma dedifferentiated liposarcoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01506596 | Phase II | Pazopanib | Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma | Completed | USA | 0 |
NCT03611868 | Phase Ib/II | APG-115 + Pembrolizumab | A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors | Recruiting | USA | AUS | 0 |
NCT03964233 | Phase I | BI 907828 + Ezabenlimab + Miptenalimab BI 907828 + Ezabenlimab | A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 in Combination With BI 754091 (Ezabenlimab) | Recruiting | USA | NLD | GBR | FRA | ESP | DEU | BEL | AUS | 3 |
NCT04028063 | Phase II | Balstilimab + Doxorubicin + Zalifrelimab | Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas | Recruiting | USA | 0 |
NCT04205227 | Phase Ib/II | ENB003 + Pembrolizumab | ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors | Active, not recruiting | USA | AUS | 0 |
NCT04438824 | Phase II | Palbociclib + Retifanlimab | Palbociclib and INCMGA00012 in People With Advanced Liposarcoma | Recruiting | USA | 0 |
NCT04668300 | Phase II | Durvalumab + Oleclumab | Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma (DOSa) | Recruiting | USA | 0 |
NCT04874311 | Phase II | Bintrafusp alfa + Doxorubicin Doxorubicin | Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma (TRUST) | Recruiting | FRA | 0 |
NCT04967521 | Phase III | Abemaciclib | SARC041: Study of Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated Liposarcoma | Recruiting | USA | 0 |
NCT04979442 | Phase III | Trabectedin Milademetan | Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma (MANTRA) (MANTRA) | Terminated | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | 6 |
NCT04996004 | Phase Ib/II | Doxorubicin + TTI-621 | A Trial of TTI-621 in Combination With Doxorubicin in Patients With Leiomyosarcoma | Terminated | USA | 0 |
NCT05043649 | Phase I | Camsirubicin + Pegfilgrastim | Camsirubicin + Pegfilgrastim to Determine MTD in ASTS | Recruiting | USA | 0 |
NCT05116683 | Phase II | ATX101 | ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma (ATX-101) | Terminated | USA | 0 |
NCT05218499 | Phase II | BI 907828 Doxorubicin | Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 11 |
NCT05580588 | Phase II | SPH4336 | Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas | Recruiting | USA | 0 |
NCT05694871 | Phase II | Cemiplimab + Palbociclib Palbociclib | Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma | Recruiting | USA | 0 |
NCT05711615 | Phase I | Pegylated liposomal doxorubicin + Peposertib | Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma | Recruiting | USA | 0 |
NCT05879185 | Phase II | Izuralimab | A Study of XmAb23104 in People With Sarcoma | Active, not recruiting | USA | 0 |
NCT05886634 | Phase II | Etrumadenant + Zimberelimab | A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma | Recruiting | USA | 0 |
NCT06058793 | Phase III | BI 907828 | Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma | Recruiting | USA | GBR | CAN | AUS | 1 |
NCT06116578 | Phase II | Pembrolizumab Olaparib + Pembrolizumab | Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab (NeoSarc) | Not yet recruiting | FRA | 0 |